Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:37:02.212Z.
Calculation as of: 2026-10-06T13:37:02.212Z.
Quote observation: 2026-10-06T13:35:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Greenwich LifeSciences, Inc.
Market Cap
$249.24M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$251.01M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$244.41M
Price/OCF Ratio
N/A
TTM Avg
252.82
3Y Avg
252.82
5Y Avg
155.13
Market Cap
$240.38M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $249.24M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $247.60M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $247.47M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.01M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $244.41M | N/A | 252.82 | 252.82 | 155.13 |
| BioAge Labs Inc. (BIOA)vs › | $241.18M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $240.55M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $240.32M | 13.44 | 11.46 | 10.55 | 21.56 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.93M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
